Coherus Oncology, Inc.CHRSEarnings & Financial Report
Nasdaq
NextMar 30, 2026
CHRS Q3 2025 Key Financial Metrics
Revenue
$11.6M
Gross Profit
$7.8M
Operating Profit
$-44.3M
Net Profit
$-35.5M
Gross Margin
67.8%
Operating Margin
-383.1%
Net Margin
-307.1%
YoY Growth
-83.7%
EPS
$-0.31
Financial Flow
Coherus Oncology, Inc. Q3 2025 Financial Summary
Coherus Oncology, Inc. reported revenue of $11.6M for Q3 2025, with a net profit of $-35.5M (-307.1% margin). Cost of goods sold was $3.7M, operating expenses totaled $52.2M.
Key Financial Metrics
| Total Revenue | $11.6M |
|---|---|
| Net Profit | $-35.5M |
| Gross Margin | 67.8% |
| Operating Margin | -383.1% |
| Report Period | Q3 2025 |
Coherus Oncology, Inc. Annual Revenue by Year
Coherus Oncology, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $267.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $267.0M |
| 2023 | $257.2M |
| 2022 | $211.0M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $91.5M | $77.1M | $65.0M | $70.8M | $54.1M | $7.6M | $10.3M | $11.6M |
| YoY Growth | 101.8% | 137.6% | 10.7% | -5.1% | -40.8% | -90.1% | -84.2% | -83.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $629.6M | $763.5M | $674.9M | $505.0M | $448.5M | $371.1M | $439.5M | $516.5M |
| Liabilities | $823.0M | $845.4M | $759.0M | $593.0M | $580.5M | $554.5M | $319.6M | $428.7M |
| Equity | $-193.4M | $-81.8M | $-84.1M | $-88.0M | $-132.0M | $-183.5M | $119.8M | $87.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-12.9M | $-46.8M | $59.7M | $-62.0M | $28.6M | $-25.8M | $-46.6M | $-46.3M |